Abstract
Hepatoblastoma can be associated with chronic kidney disease and genitourinary anomalies. Cisplatin is a key agent for treating hepatoblastoma but renal clearance and toxicity can limit its use in end-stage renal disease. We present pharmacokinetic data and clinical outcomes using cisplatin on hemodialysis for three patients with hepatoblastoma. All patients were initially treated with surgery and adjuvant cisplatin [1.67 mg/kg (2 patients) or 50 mg/m2 (1 patient)]. The patient treated with body surface area-based dosing had higher exposures and ototoxicity. Treating hepatoblastoma with cisplatin on hemodialysis using 1.67 mg/kg achieved clinical efficacy with minimal morbidity.
Original language | English (US) |
---|---|
Article number | e27425 |
Journal | Pediatric Blood and Cancer |
Volume | 66 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2018 Wiley Periodicals, Inc.
Keywords
- cisplatin
- hemodialysis
- hepatoblastoma
- pediatric oncology
- pharmacokinetics